RESUMEN
In three patients with long-standing multiple sclerosis, bullous pemphigoid developed. The diagnosis of bullous pemphigoid was based on histologic findings, direct and indirect immunofluorescence, and Western blots showing IgG reacting with the 220 to 240 kD bullous pemphigoid antigen in the serum of three patients. Contrary to previous observations, bullous pemphigoid associated with multiple sclerosis was not different from bullous pemphigoid alone. Three similar cases have been reported previously, so the occurrence of bullous pemphigoid in patients with multiple sclerosis may be more than a coincidence.
Asunto(s)
Esclerosis Múltiple/complicaciones , Penfigoide Ampolloso/complicaciones , Enfermedades Cutáneas Vesiculoampollosas/complicaciones , Anciano , Western Blotting , Femenino , Técnica del Anticuerpo Fluorescente , Humanos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/patología , Penfigoide Ampolloso/patologíaAsunto(s)
Penfigoide Ampolloso/patología , Enfermedades Cutáneas Vesiculoampollosas/patología , Femenino , Humanos , Inmunoglobulina G/aislamiento & purificación , Lactante , Masculino , Penfigoide Gestacional/complicaciones , Penfigoide Ampolloso/tratamiento farmacológico , Penfigoide Ampolloso/inmunología , Embarazo , Prurigo/complicaciones , Sulfapiridina/uso terapéuticoRESUMEN
Ro 13-7410 was given to 29 patients (a total of 38 treatment courses) for 7.5 weeks (range 4-23). This compound is one of the most potent retinoids ever synthetized and has the highest affinity to human skin cellular retinoic-acid-binding protein. At therapeutically active doses, it did not induce the commonly seen mucocutaneous signs of retinoid toxicity such as scaling and cheilitis; over 0.5 microgram/kg body weight/day, it very frequently induced an eczematous retinoid dermatitis. This pilot study provides some indications on what appears to be in several aspects a drug quite distinct from retinoids previously used in humans.